{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T04:12:20Z","timestamp":1793506340332,"version":"4.5.0"},"reference-count":59,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"am","delay-in-days":440,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.bulcan.2021.02.017","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T11:33:11Z","timestamp":1639567991000},"page":"S4-S17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"S","title":["CAR-T cells, from principle to clinical applications"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6724-6863","authenticated-orcid":false,"given":"Estelle","family":"Bourbon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Ghesqui\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Bachy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2021.02.017_bib0300","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/00000441-189305000-00001","article-title":"The treatment of malignant tumors by repeated inoculation of erysipelas: with a report of ten original cases","volume":"10","author":"Coley","year":"1893","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0305","first-page":"8","article-title":"Cancer immunotherapy: historical perspective of a clinical revolution and emerging preclinical animal models","author":"Decker","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0310","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(61)90693-6","article-title":"Immunological function of the thymus","volume":"278","author":"Miller","year":"1961","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0315","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.4049\/jimmunol.129.5.2293","article-title":"Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody","volume":"129","author":"Allison","year":"1982","journal-title":"J Immunol"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0320","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: from T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0325","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3389\/fimmu.2016.00470","article-title":"Milestones of hematopoietic stem cell transplantation - From first human studies to current developments","volume":"7","author":"Juric","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0330","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1002\/1097-0142(196611)19:11<1743::AID-CNCR2820191143>3.0.CO;2-U","article-title":"Effect of leukocytes on transplantability of human cancer","volume":"19","author":"Southam","year":"1966","journal-title":"Cancer"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0335","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0340","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"J Nat Cancer Inst"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0345","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0350","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1258\/ebm.2011.011007","article-title":"Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity","volume":"236","author":"Jochems","year":"2011","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0355","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3389\/fcell.2020.00017","article-title":"T Cell dysfunction and exhaustion in cancer","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0360","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1182\/blood-2013-11-492231","article-title":"Antibody-modified T cells: CARs take the front seat for hematologic malignancies","volume":"123","author":"Maus","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0365","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0370","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the \u03b3 or \u03b6 subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0375","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1084\/jem.178.1.361","article-title":"Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor \u03b3 chain","volume":"178","author":"Hwu","year":"1993","journal-title":"J Exp Med"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0380","doi-asserted-by":"crossref","first-page":"4318","DOI":"10.1073\/pnas.91.10.4318","article-title":"lymphocytes with a grafted recognition specificity for ERBB2- expressing tumor cells","volume":"91","author":"Moritz","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0385","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V96.5.1999","article-title":"Chimeric Fv-\u03b6 or Fv-\u025b receptors are not sufficient to induce activation or cytokine production in peripheral T cells","volume":"96","author":"Brocker","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0390","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product - PubMed","volume":"161","author":"Finney","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0395","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0400","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","article-title":"Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells","volume":"44","author":"Kawalekar","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0405","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1089\/hum.2009.122","article-title":"4-1BB and CD28 signaling plays a synergistic role in redirecting umbilical cord blood t cells against b-cell malignancies","volume":"21","author":"Tammana","year":"2010","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0410","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1016\/j.ymthe.2018.09.009","article-title":"In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell non-Hodgkin's lymphomas","volume":"26","author":"Ramos","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0415","first-page":"3","article-title":"TRUCKS, the fourth-generation CAR T cells: current developments and clinical translation","author":"Chmielewski","year":"2020","journal-title":"Adv Cell Gene Ther"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0420","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nm827","article-title":"Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15","volume":"9","author":"Brentjens","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0425","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/imt.15.77","article-title":"Targeting B-cell maturation antigen in multiple myeloma","volume":"7","author":"Tai","year":"2015","journal-title":"Immunotherapy"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0430","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/hum.2018.001","article-title":"Effective targeting of multiple B-cell maturation antigen-expressing hematological malignances by anti-B-cell maturation antigen chimeric antigen receptor T cells","volume":"29","author":"Friedman","year":"2018","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0435","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T Cell therapy for solid tumors: bright future or dark reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0440","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u201cOff-the-shelf\u201d allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0445","first-page":"24","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","author":"Lamers","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0450","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0455","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","article-title":"Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19","volume":"116","author":"Kochenderfer","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0460","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","article-title":"Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor","volume":"33","author":"Kochenderfer","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0465","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0470","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor\u2013modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0475","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0480","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0485","first-page":"8","article-title":"Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells","author":"Turtle","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0490","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor\u2013modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0495","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor t cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0500","article-title":"Long-term outcomes following CD19 CAR T cell therapy for B-ALL are superior in patients receiving a fludarabine\/cyclophosphamide preparative regimen and post-CAR hematopoietic Stem Cell transplantation","volume":"128","author":"Lee","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0505","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0510","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1038\/mt.2013.154","article-title":"Persistence and efficacy of second generation CAR T Cell against the LeY Antigen in acute myeloid leukemia","volume":"21","author":"Ritchie","year":"2013","journal-title":"Mol Ther"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0515","first-page":"10","article-title":"CAR T cells for acute myeloid leukemia: state of the art and future directions","author":"Mardiana","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0520","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/mt.2014.164","article-title":"Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia","volume":"23","author":"Wang","year":"2015","journal-title":"Mol Ther"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0525","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/j.ymthe.2017.04.017","article-title":"Balance of Anti-CD123 chimeric antigen receptor binding affinity and density for the targeting of acute myeloid leukemia","volume":"25","author":"Arcangeli","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0530","article-title":"Treating Relapsed\/Refractory (RR) AML with Biodegradable Anti-CD123 CAR modified T Cells","volume":"130","author":"Cummins","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0535","first-page":"7","article-title":"Remissions of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm following treatment with CD123-specific CAR T cells: a first-in-human clinical trial","author":"Budde","year":"2017","journal-title":"Am Soc Hematol"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0540","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-110579","article-title":"First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0545","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0550","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood\u2013brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.08.022","article-title":"Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies","volume":"183","author":"Parker","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0560","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0565","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0570","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0575","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0580","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0585","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell therapy bb2121 in relapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2021.02.017_bib0590","first-page":"1","article-title":"Clinical development of CAR T cell therapy in China: 2020 update","author":"Wei","year":"2020","journal-title":"Cell Mol Immunol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121002538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455121002538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:35:11Z","timestamp":1757792111000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455121002538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S0007455121002538"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.02.017","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T cells, from principle to clinical applications","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2021.02.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}